AI Software Gains FDA Clearance for Brain Aneurysm Detection and Follow-Up

By HospiMedica International staff writers
Posted on 19 Nov 2026

Unruptured intracranial aneurysms are often asymptomatic and can be difficult to detect on head computed tomography angiography, especially in busy acute-care workflows. Missed or delayed identification can affect management and follow-up. With an estimated one in 50 U.S. adults harboring an unruptured aneurysm, reliable interpretation remains important. A newly cleared AI-enabled system now provides concurrent detection and structured follow-up support within the radiologist’s workflow.

Bracco (Milan, Italy) and Avicenna.AI (La Ciotat, France) have received U.S. Food and Drug Administration (FDA) 510(k) clearance for UPTUNITY | Aneurysm, the first solution in Bracco’s UPTUNITY portfolio of artificial intelligence-enabled clinical decision support tools. The software is designed to assist medical specialists in detecting and assessing brain aneurysms on cerebral computed tomography angiography (CTA) images and integrates directly into the radiologist’s reading environment. The launch expands Bracco’s digital health capabilities in interpretive AI and complements its existing portfolio.


Image: Bracco and Avicenna.AI partnered in March 2026 to advance AI in contrast-enhanced CT and are now preparing to launch UPTUNITY

UPTUNITY | Aneurysm functions as computer-assisted detection and diagnosis software for concurrent use by appropriately trained medical specialists. It identifies suspected saccular brain aneurysms larger than 3 mm on head CTA and provides information on their presence, location, and size to support assessment and characterization. 

For known aneurysms, its follow-up functionality provides quantitative measurements and comparisons between examinations to help assess changes over time. The software is intended to be used alongside review of CTA images, with physicians retaining control over clinical decision-making, and is not designed to replace a complete patient evaluation or review by a qualified physician.

The companies plan the U.S. commercial introduction of UPTUNITY | Aneurysm, with Avicenna.AI leading promotion and distribution. The solution will be showcased at the Radiological Society of North America 2026 Annual Meeting, November 29–December 3, in Chicago.


Latest Medical Imaging News